Wilderness medicine at high altitude: recent developments in the field. by Shah, NM et al.
© 2015 Shah et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Open Access Journal of Sports Medicine 2015:6 319–328
Open Access Journal of Sports Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
319
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OAJSM.S89856
wilderness medicine at high altitude: recent 
developments in the field
Neeraj M Shah1
Sidra Hussain2
Mark Cooke3
John P O’Hara3
Adrian Mellor3,4
1Division of Asthma, Allergy and 
Lung Biology, King’s College London, 
UK; 2School of Medicine, University 
College London, London, UK; 
3Research institute for Sport, Physical 
Activity and Leisure, Leeds Beckett 
University, Leeds, UK; 4Academic 
Department of Military Anaesthesia 
and Critical Care, Royal Centre for 
Defence Medicine, Birmingham, UK
Correspondence: Neeraj M Shah 
49 Bodley Road, New Malden,  
Surrey KT3 5QD, UK 
Tel +44 7739 576 115 
email neeraj.shah@nhs.net
Abstract: Travel to high altitude is increasingly popular. With this comes an increased incidence 
of high-altitude illness and therefore an increased need to improve our strategies to prevent 
and accurately diagnose these. In this review, we provide a summary of recent advances of 
relevance to practitioners who may be advising travelers to altitude. Although the Lake Louise 
Score is now widely used as a diagnostic tool for acute mountain sickness (AMS), increasing 
evidence questions the validity of doing so, and of considering AMS as a single condition. 
Biomarkers, such as brain natriuretic peptide, are likely correlating with pulmonary artery 
systolic pressure, thus potential markers of the development of altitude illness. Established 
drug treatments include acetazolamide, nifedipine, and dexamethasone. Drugs with a potential 
to reduce the risk of developing AMS include nitrate supplements, propagators of nitric oxide, 
and supplemental iron. The role of exercise in the development of altitude illness remains hotly 
debated, and it appears that the intensity of exercise is more important than the exercise itself. 
Finally, despite copious studies demonstrating the value of preacclimatization in reducing the 
risk of altitude illness and improving performance, an optimal protocol to preacclimatize an 
individual remains elusive.
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Introduction
Travel to high altitude is increasingly popular. In a 12-month period, UK-based  commercial 
companies offered 93 expeditions to climb Mount Kilimanjaro (5,895 m) alone.1 With 
increasing popularity comes an increased incidence of high-altitude illness. It is not a 
problem at extreme altitude only; 25% of conference attendees at a medical conference 
in the Rocky Mountains, at elevations of ∼2,000 m, reported symptoms attributable to 
acute mountain sickness (AMS).2 With .120 million people visiting the European Alps 
each year at similar altitudes,3 this is a significant public health problem.
In this review, we aim to summarize the recent advances in this field of relevance 
to sports and travel medicine practitioners who may be advising travelers to high alti-
tude (2,500–5,500 m) or extreme altitude (.5,500 m). After summarizing the basic 
 physiological changes that occur at high altitude and the illnesses that accompany them, 
we discuss some novel approaches to diagnosing and monitoring altitude illness. We 
then go on to discuss novel pharmacological treatments that may be of use and ways 
in which travelers may be able to prepare themselves to cope with high altitude.
Adaptation to altitude
With ascent to high altitude, barometric pressure and therefore the partial pressure of 
oxygen in inspired air fall. The atmospheric pressure at sea level is 760 mmHg, whereas 
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at 5,500 m above sea level (the altitude of Everest Base Camp, 
a popular trekking destination), it is 380 mmHg. Halving the 
amount of oxygen in inspired air has profound effects on 
human physiology. In an unacclimatized individual, this will 
immediately result in breathlessness and reduced exercise 
tolerance. Arterial oxygen saturations may be ,80%,4 and at 
extreme altitude, arterial oxygen saturations as low as 34% 
are recorded in healthy individuals.5
Acute exposure to such low oxygen tensions would cause 
unconsciousness within minutes,6 yet certain individuals 
are able to climb as high as the summit of Mount Everest 
(8,848 m) without supplementary oxygen. The physiological 
changes that take place to adapt to this hypoxic  environment 
are known as acclimatization. On immediate exposure, there is 
a rise in heart rate and respiratory rate followed by a  diuresis, 
which decreases plasma volume (increasing  hematocrit) and 
produces an acidemia secondary to bicarbonate  excretion. To 
increase the oxygen-carrying capacity of the blood, hemoglo-
bin production will increase and a rightward shift of the oxygen 
dissociation curve will alter the oxygen- binding  capacity of 
hemoglobin.4 The physiological changes are highly individual 
and in a proportion of individuals, high-altitude illness may 
occur if they ascend to high altitude (.3,500 m) more quickly 
than their physiology adapts to the hypoxic conditions.
High-altitude illnesses
High-altitude illness present in various forms, all of which 
form a spectrum of disease, encompassing AMS, high- altitude 
pulmonary edema (HAPE), and high-altitude cerebral edema 
(HACE).
The most common illness is AMS. It is present in 
up to 75% of individuals on common trekking routes.7,8 
Common symptoms include headache, nausea, fatigue, 
dizziness, anorexia, and sleep disturbance. Diagnosis of 
AMS is  difficult as none of the symptoms are specific to it. 
Furthermore, no physiological variable has been validated 
to effectively detect the onset of AMS. The Lake Louise 
Score (LLS) was developed for research purposes to define 
AMS,9 using subjective, nonspecific symptoms. As there 
is no underlying mechanism to explain this collection of 
symptoms together, it is now less widely accepted that 
they be grouped together as one disease.10 The prevailing 
pragmatic approach to its management, however, is that if 
an individual is unwell with a headache at altitude, and no 
other cause can be found, they should be treated as having 
AMS. Management involves descent and simple analgesia, 
with the addition, in more severe cases, of supplemental 
oxygen, hyperbaric chamber, acetazolamide (a carbonic 
anhydrase inhibitor causing diuresis), and dexamethasone 
(a potent glucocorticoid that reduces symptoms).
Most deaths at high altitude are caused by HAPE.11 It 
occurs when intravascular fluid leaks out into the  extravascular 
space, impeding gaseous exchange. It seems the most likely 
 etiology is an exaggerated hypoxic pulmonary  vasoconstrictive 
response, resulting in a raised pulmonary artery systolic 
 pressure (PASP) and a subsequent  transudative capillary 
leak.12 It tends to occur 2–4 days after arrival at high altitude, 
presenting initially with shortness of breath on exertion and 
deteriorating to shortness of breath at rest, accompanied by a 
wet cough, hemoptysis, orthopnea, chest pain, headache, and 
confusion. It is frequently associated with AMS or HACE. 
Management of HAPE involves rapid descent, supplemen-
tal oxygen, nifedipine (a  dihydropyridine calcium channel 
blocker), or sildenafil to bring about  pulmonary vasodilata-
tion and the use of a hyperbaric  chamber if descent is not 
possible.4
HACE usually follows on from AMS. The mechanism 
underlying this is not clear, but the tight-fit hypothesis has 
been mooted as a possible explanation. This suggests that 
individuals with less compliant cerebrospinal fluid systems 
have a greater increase in intracranial pressure (ICP) for any 
given increase in brain volume, resulting from cerebral edema 
and leads to neurological compromise. Limited data have 
demonstrated a dramatic increase in ICP in individuals with 
AMS compared to those without, and this may support this 
theory.13,14 Although most cases are preceded by a prodrome 
of AMS-like symptoms, occasionally HACE can develop 
suddenly in previously fit individuals.15 Symptoms include 
headache, nausea, hallucination, disorientation, confusion, 
and reduced consciousness. Management includes rapid 
descent, supplemental oxygen, and dexamethasone.
Both HAPE and HACE are medical emergencies, and it 
is imperative that individuals suffering from these conditions 
are evacuated back down to a safer altitude straightaway. It is 
particularly important as although the medications discussed 
are evidence based and recommended in the most recent inter-
national guidelines on managing altitude illness,16 it appears 
that commercial operators do not routinely carry them.17 It is 
equally important, therefore, that we have reliable and accurate 
tools to predict and diagnose these conditions.
Diagnosis of AMS
Lake Louise Scoring system
Despite its development as a research tool, the LLS is 
widely used to diagnose AMS. Headache must be present 
for the diagnosis of AMS with at least one other  symptom 
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(gastrointestinal symptoms, fatigue and/or weakness, dizzi-
ness,  difficulty sleeping). Each symptom is scored from 0 
(none) to 3 (severe). A total score of 3 or more in the  presence 
of a headache is diagnostic for AMS.9 The use of this score 
has been  validated in a recent normobaric hypoxia chamber 
study.18 Much has been published about the utility and value 
of headache being a discriminatory feature of AMS. The 
incidence of headache at altitude is up to 100% .4,500 m.19 
A survey on Mount  Damavand reported that 87% of  trekkers 
at high altitude suffer from a headache.20 Of these, 70% had 
other features suggestive of AMS. This suggests that 30% of 
 trekkers have headache that is not related to AMS,  questioning 
the validity of using headache as a compulsory feature of an 
AMS  diagnosis. Other causes of headache at altitude can 
include dehydration, migraines, tension  headaches, sinusitis, 
and frontal muscle  contraction from sun glare. Headache 
pattern may be useful in AMS  diagnosis; 100% of trekkers 
with an occipital headache and 83% of those with a temporal 
headache had other features of AMS.20 This is supported by 
a study  measuring changes in cerebral hemodynamics after 
acute exposure to altitude, which  demonstrated significantly 
greater blood flow in the posterior cerebral circulation in 
 individuals suffering from AMS, compared with those  without 
symptoms.21 It seems occipital or temporal headaches at high 
altitude are almost diagnostic for AMS, and there is, perhaps, 
a need for the headache of AMS to be characterized as such. 
The issue of whether headache should be afforded preponder-
ance remains hotly debated.22,23 While the place of headache 
in the diagnosis of AMS is being debated, an algorithm has 
been developed for assessing individuals with headache at 
altitude, using a pragmatic approach, taking into account a 
past medical history of headache-associated illness and other 
features consistent with AMS.24
The place of poor sleep quality in the diagnosis of AMS 
has also been questioned. A large symptomatology analysis 
using a novel correlation networks  methodology  demonstrated 
two clusters of symptoms, one with a  preponderance of 
 individuals with poor sleep quality and the other with head-
aches.10 Few individuals suffered from both headaches and 
poor sleep quality. Another study demonstrated a poor cor-
relation between poor sleep quality and the other features 
of AMS, and that by eliminating sleep from the score, the 
repeatability of an AMS diagnosis was stronger.25
Biomarkers
Biomarkers can be useful tools to predict or diagnose high-
altitude illness if demonstrated to be reliable and accurate. 
They may also have utility in tracking an individual’s illness 
to assess satisfactory resolution following treatment. With 
the development of simple point-of-care diagnostic systems, 
these may have utility for diagnosis in the field.
The association between brain natriuretic peptide (BNP) 
and congestive cardiac failure has raised an interest in its use 
as a biomarker in both AMS and HAPE. It is a  neurohormone, 
primarily secreted by cardiac ventricular  myocytes in response 
to stretching, caused by fluid overload. Its release results in a 
reduction in systemic vascular resistance and central venous 
pressure and an increase in natriuresis;  leading to a decrease 
in blood volume and systemic blood  pressure, which in turn 
leads to an increase in cardiac  output.26  Clinically, it rises 
in proportion to increasing severity of heart failure and is 
thus used as a marker of the extent of heart failure. As AMS 
is associated with fluid retention,27 it would lead to  cardiac 
stretch and BNP release. Using point-of-care monitoring 
systems, Woods et al reported that elevated BNP levels are 
significantly correlated with severe AMS diagnosed using 
the LLS.28 As discussed earlier, elevated PASP is important 
in the development of HAPE.12 Elevated BNP levels are also 
associated with elevated PASP,29,30 and BNP reduces with 
improving symptoms once HAPE has been treated.31,32 All 
of these recent studies suggest that BNP may have value as 
biomarkers for HAPE and could have utility in prescreening 
individuals of risk, and more importantly, with the advent of 
point-of-care testing technology, diagnosing patients with 
HAPE. In the field, this may help to discriminate between 
a simple chest infection requiring antibiotics and HAPE 
requiring immediate evacuation.
Asymmetric dimethylarginine (ADMA), a nitric oxide 
synthase inhibitor, was investigated as a marker of PASP 
in a hypobaric chamber study.33 Although no relationship 
was demonstrated between elevated ADMA and PASP or 
AMS, a significant decrease in ADMA was correlated with 
AMS and PASP .40 mmHg (the threshold for diagnosing 
HAPE). Furthermore, the change in ADMA 2 hours after 
exposure to hypoxia was predictive for LLS .5. Much 
more work is needed to determine its validity; however, this 
study  demonstrates that there may be potential for the use of 
ADMA as a predictive biomarker for AMS and HAPE.
Using the prevailing opinion that oxidative stress is a 
contributory factor to the development of high-altitude ill-
ness,4 work has been done on the potential of using markers 
of oxidative stress to predict or diagnose AMS. The levels 
of neutrophil gelatinase-associated lipocalin, a marker of 
oxidative stress in the lungs, increased during trekking 
expeditions to .5,000 m, is correlated with the severity of 
AMS.34 Carbonyl proteins, also markers for oxidative stress, 
Open Access Journal of Sports Medicine 2015:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
322
Shah et al
increase in proportion to the severity of AMS.35 Conversely, 
a proteomic analysis has suggested that individuals with AMS 
had higher expression of antioxidants than those without, 
 questioning the presumed benefit of antioxidants in the protec-
tion against and  management of AMS. The study concludes 
by speculating that this overexpression may be compensation 
for  hypoxia-induced free radical species production.36
The picture with biomarkers of altitude illness is very 
 complex; a proteomic analysis of plasma proteins in rats 
exposed to hypoxia has identified 25 proteins whose  expression 
changed with hypoxia.37 Any of these may prove useful; 
 however, the goal remains to find a marker of altitude illness 
for clinical use and acclimatization for research studies.
Novel drug treatments for AMS
Established drug treatments include acetazolamide, dexam-
ethasone, and nifedipine. Acetazolamide is thought to be 
effective in treating AMS, creating an acidemia, increasing 
ventilation, and therefore, increasing the arterial oxygen 
content.38 Dexamethasone is effective at reducing edema and 
symptoms in HACE, just as it is in any other form of cerebral 
edema. Nifedipine is used in HAPE for its dilatory effect 
on the pulmonary vasculature; however, a recent study did 
not demonstrate any benefit over descent and supplemental 
 oxygen in patients with HAPE.39 In addition to these estab-
lished  treatments, potential novel therapies have been sug-
gested such as ibuprofen, nitrates, and intravenous (IV) iron 
supplementation.
ibuprofen
Other than the tight-fit hypothesis previously discussed, 
other possible mechanisms causing high-altitude head-
ache include activation of the trigeminovascular system 
by  vasodilatation or inflammatory mediators40,41 or altera-
tion in the blood–brain barrier by inflammatory mediators 
 causing vasogenic  edema.13 The central role of inflammation 
in these  mechanisms has led to the interest in nonsteroidal 
 anti-inflammatory medications such as ibuprofen.
A meta-analysis encompassing the only three  randomized 
controlled trials (RCTs) in the literature comparing the 
effect of ibuprofen against placebo in high-altitude head-
ache42–44 demonstrated a significant improvement in LLS 
with  ibuprofen over placebo.45 However, it is  perhaps not 
 surprising that compared to placebo, a known  headache 
 medication resulted in an improvement in any form of 
 headache. A further RCT comparing ibuprofen with 
 acetazolamide has demonstrated equivalent effects on the 
severity of AMS using LLS,46 further supporting the theory 
that inflammation plays a part in the development of AMS 
and, in particular, high-altitude headache. Based on these 
trials, the most recent international guidelines on treatment 
of acute altitude illness do not recommend the routine use 
of ibuprofen as prophylaxis against AMS.16
Nitrates
Nitric oxide (NO) regulates physiological processes in the 
human body, including vasodilation, immune function, plate-
let aggregation, glucose homeostasis, muscle contraction, 
and mitochondrial function. Emerging evidence suggests that 
NO also plays an important role in altitude  acclimatization. 
Lowlanders exposed to altitude initially exhibit reduced 
concentrations of exhaled NO, with the magnitude of this 
decline associated with susceptibility to altitude illness.47 
With acclimatization, lowlanders demonstrate an increase 
in NO production.48 The adaptive response to hypoxia is 
particularly prominent in Tibetans who have greater plasma 
nitrite concentrations, indicative of elevated whole-body NO 
production,49 and higher exhaled NO relative to lowlanders.50 
This affords them unique physiological advantages that 
result in a remarkable capacity to cope with the challenges of 
hypoxia relative to lowlanders. Therefore, given the impor-
tance of NO during altitude acclimatization, it is tempting 
to speculate that interventions increasing NO availability, 
especially during acute (ie, prior to acclimatization) and 
chronic altitude exposure (ie, during acclimatization), may 
be advantageous.
One possible means of eliciting this effect is via dietary 
nitrate supplementation (ie, nitrate-rich beetroot juice). 
Nitrate ingestion has been shown to increase plasma con-
centrations of NO metabolites (nitrate and nitrite),51 reduce 
steady-state oxygen consumption,52 improve arterial and 
tissue oxygenation,53 enhance exercise tolerance,53–55 and 
improve performance,56 during acute normobaric hypoxia. 
Interestingly, under hypoxic conditions, nitrate supplemen-
tation in the form of beetroot juice resulted in faster muscle 
recovery and restored maximal oxidative ATP resynthesis 
and exercise tolerance to normoxic values, when compared 
to placebo.54,57 The mechanisms underlying these effects 
are still under investigation, but may involve improved 
mitochondrial,58 and/or muscle contractile efficiency,59 
and enhanced tissue blood flow/better matching of oxygen 
 delivery to metabolic rate.60
It is the prevailing opinion that AMS is triggered by a 
fall in arterial oxygen saturation (ie, hypoxemia) subsequent 
to hypoxic exposure.61 Therefore, improved arterial oxygen 
saturation with nitrate ingestion may be expected to reduce 
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the incidence of AMS. There was no difference in mean 
AMS scores between participants consuming  nitrate-rich 
beetroot juice and a nitrate-free placebo during acute 
(∼2 hours)  exposure to extreme normobaric hypoxia (FiO
2
 
11%, ∼5,000 m).53 However, six out of ten individuals were 
diagnosed positive for AMS with placebo ingestion versus 
only four with the ingestion of nitrate-rich beetroot juice. It 
is possible that the potential for nitrate to attenuate AMS may 
become more pronounced during more prolonged (.2 hours) 
or extreme hypoxic exposure (for example, a high-altitude 
expedition), though this is yet to be established.
Both sildenafil (a selective phosphodiesterase type 5 
[PDE-5] inhibitor) and  bosentan (a nonselective endothelin-
receptor antagonist) have been mooted as potential treat-
ments for AMS, due to their effect on prolonging the effect 
of NO. Sildenafil has been demonstrated to reduce PASP, 
increase oxygen delivery, and minimize the decrease in 
exercise capacity in both normobaric hypoxia and actual 
high altitude.62 By dilating the pulmonary vascular bed, these 
drugs reduce the degree of hypoxic pulmonary vasoconstric-
tion and consequent pulmonary hypertension, and therefore, 
the risk of HAPE. Theoretically, this could improve exercise 
tolerance under hypoxic conditions. Indeed, they have been 
demonstrated to improve arterial oxygen saturations in 
individuals exercising at altitude.63,64 However, trials have 
failed to demonstrate an improvement in exercise capacity63 
or incidence of AMS and HAPE.65 In fact, higher rates of 
AMS were reported in individuals treated with sildenafil, 
compared to placebo.65 This may be because headache is 
a recognized side effect of sildenafil, thus increasing an 
individual’s LLS. Therefore, although there appears to be 
an improvement in arterial oxygen saturation with these 
medications, there does not appear to be a consequent 
improvement in function.
iv iron supplementation
Supplemental iron has been demonstrated to reverse hypoxia-
induced pulmonary hypertension, while iron depletion results 
in increased pulmonary artery pressure.66,67 The  mechanism 
for this and its potential benefit in AMS are thought to be 
due to its effect on hypoxia-inducible transcription factors 
(HIF). Excess iron decreases the stability of HIF, while iron 
depletion increases its stability.68,69 In hypoxic  conditions, 
 oxygen-dependent hydroxylase enzymes are unable to 
degrade HIF, so iron supplementation encourages the 
 breakdown of HIF, as in normoxic conditions. This is sig-
nificant as HIF is believed to coordinate the cellular inflam-
matory response to hypoxia.70
IV iron supplementation immediately prior to ascent to 
high altitude resulted in a significantly lower rise in AMS score 
from sea level to altitude, compared to IV saline. However, 
there was no significant  difference in  absolute AMS score at 
altitude between the two groups.70 Iron supplementation is an 
intriguing prospect in the prophylactic management of AMS; 
however, its feasibility on field expeditions is questionable. 
Oral iron supplemental is a possible alternative that needs 
more investigation.
Exercise and AMS
While the exact mechanism underlying high-altitude  illness 
remains hotly debated, exercise has been suggested as an 
independent risk factor for the development of AMS.71 
 High-intensity intermittent exercise on a trekking  expedition 
was associated with increased interstitial lung fluid at 
4,090 m,72 suggesting that exercise increases the risk of HAPE. 
Corroborating this, AMS scores were  significantly higher in 
trekkers with higher rating of perceived exertion.73
Conversely, several recent chamber studies have failed 
to demonstrate a statistical difference in the development 
of AMS between rest and exercise at simulated altitude.74–76 
Of note, in comparing the change in interstitial fluid 
between exercise in hypoxia at 4,090 m and exercise in 
simulated hypoxia, there was no significant increase in 
simulated hypoxia, while there was an increase in actual 
hypoxia.72 This suggests that chamber studies are possibly 
underestimating the effect of exercise on the development 
of AMS and HAPE, and that this may be due to the dif-
ference between the normobaric hypoxia experienced in 
chamber studies and hypobaric hypoxia experienced at 
altitude.77
It has been hypothesized that exercise causes AMS by 
its effect on cortisol. AMS and HACE are fluid-retention 
states. Although high-altitude exposure tends to cause a 
marked diuresis and natriuresis, due to reduced aldosterone, 
numerous studies have reported an increase in cortisol at 
rest under hypoxic conditions.78 Exercise leads to a surge in 
cortisol levels at sea level, and so it has been hypothesized 
that by exercising at altitude, a large surge in cortisol is trig-
gered, leading to fluid retention and possibly AMS. Cortisol 
levels measured in response to exercise did not demonstrate a 
significant increase at 4,270 m, but did at 5,150 m.78 Similarly, 
up to 3,750 m, there was no significant increase in cortisol 
levels with exercise and no difference between hypoxia and 
normoxia.79 Exercise may also play a role in promoting a 
stress response involving arginine vasopressin, which would 
increase fluid retention.80
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Increase in brain volume and cerebral edema have been 
reported in response to hypoxia in patients with AMS.81,82 
A possible explanation for this is the cortisol surge seen 
in response to exercise; however, despite demonstrating 
an overall increase in white matter volume in response to 
hypoxia, there was no reported difference in the volume 
change between rest and exercise.76 There was also no 
relationship between development of AMS and change in 
cerebral  volume. A study investigating the effect of exercise 
on markers of oxidative stress in normobaric hypoxia dem-
onstrated that moderate-intensity exercise reduces oxidative 
stress, suggesting that exercise is protective against AMS, 
not causative.83
From the information presented earlier, it appears that 
the role of exercise may be complex and related to intensity 
of exercise rather than undertaking any exercise.
Is preacclimatization helpful?
Altitude acclimatization is a series of physiological responses 
that compensate for the reduction in the partial pressure 
of oxygen with increasing altitude.84 If acclimatization is 
inadequate, the frequency and severity of illnesses such 
as AMS increases.85 Continuous exposure to terrestrial 
altitudes .3,000 m reduces the susceptibility to AMS at 
very high altitudes (.3,500 m)86 and improves the exercise 
performance.87 However, it is not always feasible to spend 
time at high altitude before an expedition. Acclimation (or 
preacclimatization) describes the physiological responses 
associated with acclimatization but as a result of techniques 
other than continuous exposure to terrestrial altitude.88 
Intermittent hypoxic exposure (IHE) is passive exposure 
to hypoxia lasting from seconds to hours that is repeated 
over several days to weeks,89 interspersed with normoxia. 
 Intermittent hypoxic training (IHT) is the use of intermittent 
hypoxia with periods of exercise.
There are two key papers that underpin the evidence for 
use of preacclimatization. Richalet et al90 used an acclima-
tion protocol that comprised of a 1-week sojourn on Mont 
Blanc (between 4,350 m and 4,807 m) and then 4 days of 
IHE (from 5,000 m to 8,500 m) in a hypobaric chamber 
(∼10 hours per day, total of 38 hours). This resulted in a 
12% increase in hemoglobin and a 7% increase in arterial 
oxygen saturation (SaO
2
) (75%±4%–82%±3%) during sub-
maximal exercise (70% of VO
2max
) in normobaric hypoxia 
(FIO
2 
=0.115, ∼4,800 m). Climbers subsequently reached 
7,800 m only 5 days after leaving base camp, gaining 
5,600 m in only 6 days. Conventional expeditions would 
reach the same altitude in 12–32 days. A similar study using 
continuous preacclimatization on Mont Blanc and IHE in a 
hypobaric chamber induced sufficient adaptation to allow 
rapid progression to extreme altitude, saving 1–2 weeks of 
acclimatization.88
In terms of the hematological adaptations associated with 
acclimation, there is conflicting evidence, with some studies 
reporting no significant erythropoetic effect as a result of 
IHE,91,92 while others have shown significant increases in both 
red blood cell count and hemoglobin (10.8%–12%).93–95 This 
may be due to differences in the magnitude of hypoxic  stimulus 
(duration, frequency, and number of exposures), as well as 
the difference in  physiological responses documented,96–98 
between  hypobaric- and  normobaric-simulated altitudes. 
 Comparisons between modes of hypoxic stimulus show that 
there are very few normobaric hypoxic studies that have 
produced significant hematological  adaptations.99 In contrast, 
there is greater consistency in the reported improvements in 
hypoxic  ventilatory response, using both normobaric100,101 and 
hypobaric chambers,102,103 though hypobaricity seems to be 
consistently more  effective. With regard to exercise perfor-
mance, Beidleman et al have  conducted many studies,85,86,104–106 
using various  methodologies from 1 week106 to 3 weeks,104 
on IHE (hypobaric, 4,300 m),  reporting significant improve-
ments in cycle time-trial performance (16%–21%). However, 
they also reported no significant changes in cycle time-trial 
performance at 4,300 m  following 7 days of normobaric IHE 
at 4,500 m.105 It is worth noting, however, the length of time 
(60 hours) between the completion of final exposure and 
the post IHE time trial. Furthermore, it is important to note 
that none of the aforementioned studies have then assessed 
the effectiveness of acclimation during an expedition to 
 terrestrial altitude.
Studies comparing the use of IHE and IHT have typically 
reported no significant differences between groups in any 
physiological or performance variables, suggesting there is 
no additional benefit associated with exercising on exposure 
to hypoxia, even with an exercise-induced hypoxemia.104,105 
Research is, however, limited on the extent to which the exer-
cise stimulus has been explored, ie, time, intensity, and range 
of altitudes compared. There remains a sound physiological 
rationale that supports the hypothesis that there are benefits 
associated with the inclusion of exercise in hypoxic expo-
sures. Even without significant physiological adaptations, a 
reduction in perceptual effort and familiarity with the level 
of exertion required to perform at altitude may reduce the 
psychological strain and impact of expeditions, thereby facili-
tating subsequent performance at terrestrial altitude. Given 
the requirement for sustained vigorous endurance exercise 
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on high-altitude expeditions, more research is required to 
evaluate the potential benefits of IHT.
Presently, the research suggests that hypobaric hypoxia, 
in comparison to normobaric hypoxia, is more effective in 
stimulating acclimatization,96 which is consistent with that 
of terrestrial altitude exposure. IHE for .1 hour per day and 
.4,000 m for a period of 1–3 weeks increases peripheral 
capillary oxygen saturation (SpO
2
), reduces symptoms of 
AMS, improves exercise performance, and reduces the physi-
ological stress associated with high-altitude exposure.85,104 
However, the optimal acclimation protocol is yet to be estab-
lished, with more research required,  particularly into the use 
of normobaric hypoxia, which is more easily accessible to 
a wider population.
inspiratory muscle training
In addition to IHE and IHT, there are other potential 
 techniques such as dietary nitrate supplementation (which 
has been discussed earlier) and inspiratory muscle training 
(IMT), which may attenuate arterial oxygen desaturation 
and a reduction in exercise performance during high-altitude 
exposure.
Acute exposure to hypoxia and the associated reduction 
in the arterial partial pressure of oxygen increases minute 
ventilation, in an attempt to normalize arterial oxygen 
 saturation. However, this hyperventilation increases the work 
of breathing and in turn the demand for  respiratory blood 
flow,107 making the respiratory muscles more  susceptible 
to fatigue. This is likely to be further accentuated during 
 exercise at altitude. Four weeks of IMT has been shown 
to reduce inspiratory muscle fatigue following  exhaustive 
exercise by ∼10% in normobaric hypoxia (FIO
2
=0.14, 
∼3,050 m), as well as attenuating the reduction in SpO
2
 by 
∼5%.108 The mechanism is not clearly defined, but the fact 
that IMT decreased cardiac output and increased lung diffu-
sion capacity suggests that red blood cell transit time in the 
pulmonary capillary was prolonged. Further, dyspnea and 
rating of perceived  exertion were reduced following exhaus-
tive exercise. The latter may be important as the incidence 
of AMS has been shown to be higher following trekking 
days with high ratings of perceived exertion.73 Interestingly, 
reductions in arterial desaturation were not observed at 
rest,108 suggesting that the cardiopulmonary stress was not 
significant enough at ∼3,050 m in normobaric hypoxia. In 
contrast, 4 weeks of IMT only attenuated the reduction in 
SpO
2
 (6%) during rest at altitudes of 4,880 m and 5,550 m 
on a high-altitude expedition, suggesting an upper threshold 
for its effectiveness.109 Even though these studies show some 
promising findings, neither has assessed whether IMT can 
reduce an individual’s susceptibility to AMS. Therefore, 
further research is required to establish whether IMT is an 
effective preexpedition strategy.
Conclusion
As the number of people traveling to altitude increases, 
the risk of life-threatening medical emergencies will also 
increase, and therefore, it is important that we have effective 
strategies to minimize their risk and accurately diagnose 
these conditions. Although the LLS was developed as a 
research tool, it is now widely used as a diagnostic tool 
for AMS. Several studies have questioned the validity of 
components of the LLS, such as headache and sleep, and 
suggested splitting the collection of symptoms known as 
AMS into separate conditions. Interest in biomarkers to 
predict the performance at altitude and risk of developing 
altitude disease has grown significantly. The use of BNP as 
a marker of PASP has been investigated considerably, and 
with further validation, studies may be an effective marker 
of HAPE. Interest in medications that may reduce the risk 
of altitude disease has expanded to nitrate supplementation 
and medications that propagate the effects of nitric oxide 
and to iron supplementation. The role of exercise in the 
development of altitude diseases remains hotly debated; 
current literature suggests that the intensity of exercise is 
more important than exercise itself. Finally, despite numer-
ous studies suggesting that preacclimatization training may 
be helpful in reducing the risk  of altitude  illness, an optimal 
protocol for preacclimatization continues to be elusive. The 
science and medicine of altitude have developed significantly 
to the benefit of travelers and practitioners advising them; 
however, several key questions remain unanswered, and it 
is crucial that these are addressed so that we can advise 
travelers appropriately.
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